Pregled bibliografske jedinice broj: 824034
The Use of Statins Is Associated with Insulin Sensitivity Decrease in Type 1 Diabetes Mellitus: Prospective Observational Study
The Use of Statins Is Associated with Insulin Sensitivity Decrease in Type 1 Diabetes Mellitus: Prospective Observational Study // Diabetes Care
New Orleans (LA), Sjedinjene Američke Države, 2016. str. 629-629 (poster, međunarodna recenzija, sažetak, znanstveni)
CROSBI ID: 824034 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
The Use of Statins Is Associated with Insulin Sensitivity Decrease in Type 1 Diabetes Mellitus: Prospective Observational Study
Autori
Duvnjak, Lea ; Blaslov, Kristina
Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, znanstveni
Izvornik
Diabetes Care
/ - , 2016, 629-629
Skup
American Diabetes Association Annual Meeting
Mjesto i datum
New Orleans (LA), Sjedinjene Američke Države, 10.06.2016. - 14.06.2016
Vrsta sudjelovanja
Poster
Vrsta recenzije
Međunarodna recenzija
Ključne riječi
type 1 diabetes mellitus; insulin sensitivity; statins
(type 1 diabetes mellitu; insulin sensitivity; statins)
Sažetak
Statins are effective in the primary and secondary prevention of cardiovascular events in diabetes mellitus (DM). Emerging evidence suggest that statins might reduce insulin sensitivity and secretion. We investigated the effect of statin therapy introduction on insulin sensitivity in type 1 DM patients (N=832) aged 25-61 years during 5 year follow up. Insulin sensitivity was accessed using equation derived from euglycemic-hyperinsulinemic clamp studies-estimated glucose disposal rate (eGDR). Patients who started statin therapy (N= 345, 41.47% ; 59.42% atorvastatin and 40.58% simvastatin) showed a greater insulin sensitivity decrease (19.27 % vs 12.82 %, p<0.001) and metabolic control deterioration compared to statin free group (Table). The risk of insulin sensitivity decrease attributable to statin use was 36.7% (HR 1.36 (1.31-1.43) after adjustments for age, gender, disease duration, smoking status and the concomitant antihypertensive therapy. Patients on statins were further divided according to the median percentage of eGDR reduction (19.27%) which revealed that the risk of eGDR reduction was significantly atributable to baseline glycated haemoglobin (HR 1.96 ; 95%CI 1.61-2.39). The cardiovascular benefits of statin treatment might outweigh the risk of developing insulin resistance, but the possible metabolic control worsening merits to be considered.
Izvorni jezik
Engleski
Znanstvena područja
Kliničke medicinske znanosti
POVEZANOST RADA
Ustanove:
Klinika za dijabetes, endokrinologiju i bolesti metabolizma Vuk Vrhovac
Profili:
Lea Smirčić-Duvnjak
(autor)